Advair Relaunch And Nasal Naloxone Nod Raise Hikma’s Expectations
Also Strikes Branded Injectables Deal With Melinta For MENA Region
Fresh from resuming launch of its generic version of Advair in the US, Hikma has also been boosted by an FDA approval for its 505(b)(2) naloxone 8mg nasal spray. Both developments are expected to drive the firm’s generics business to the top end of its guidance for 2021, management revealed.
You may also be interested in...
Hikma has delivered on one of its key US launches for 2021 by introducing its Kloxxado naloxone 8mg nasal spray for the emergency treatment of known or suspected opioid overdose, after the 505(b)(2) product was approved by the FDA earlier this year.
The generics industry struggled with the prior-year comparison as it saw an expected decline in revenues in the first quarter of 2021, driven by the global impact of the COVID-19 crisis. As a result, the performance of most companies fell short of the numbers reported in Q1 2020. However, a few managed to contradict the trend by reporting growth, either based on the launch of COVID-related drugs or performance in specific geographies.
Hikma has added three products – a generic version of Banzel tablets and injectables ganciclovir and doxycycline – to its US portfolio.